pyrroles has been researched along with evacetrapib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD | 1 |
| Krueger, KA; Morisaki, Y; Ruotolo, G; Takeuchi, M; Teramoto, T | 1 |
2 trial(s) available for pyrroles and evacetrapib
| Article | Year |
|---|---|
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Reference Values; Risk Assessment; Treatment Outcome | 2014 |